Anaptysbio (ANAB) Operating Expenses (2016 - 2026)

Anaptysbio has reported Operating Expenses for 11 years, with the latest figure at $60.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 8.83% year-over-year to $60.2 million; the trailing twelve-month figure through Mar 2026 stood at $191.6 million (down 9.7% YoY), and the FY2025 full-year result was $186.7 million, down 9.47% from the prior year.
• Operating Expenses for Q1 2026 stood at $60.2 million, up from $41.3 million in the prior quarter.
• The five-year high for Operating Expenses was $60.2 million in Q1 2026, with the low at $29.0 million in Q2 2022.
• Historically, Operating Expenses has averaged $44.7 million across 5 years, with a median of $45.8 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Expenses soared 56.01% — and 2025, when it decreased 21.66%.
• Anaptysbio's Operating Expenses stood at $32.8 million in 2022, then soared by 56.01% to $51.1 million in 2023, then rose by 3.21% to $52.8 million in 2024, then slipped by 21.66% to $41.3 million in 2025, then jumped by 45.58% to $60.2 million in 2026.
• The last three Operating Expenses figures came in at $60.2 million (Q1 2026), $41.3 million (Q4 2025), and $41.6 million (Q3 2025), per Business Quant data.